Antiplatelet drugs

Aspirin () is the genericized trademark for acetylsalicylic acid (ASA), a nonsteroidal anti-inflammatory drug (NSAID) used to reduce pain, fever, and inflammation, and as an antithrombotic. Aspirin is used to treat inflammatory conditions including Kawasaki disease, pericarditis, and rheumatic fever.

Dipyridamole, sold under the brand name Persantine among others, is an antiplatelet drug of the nucleoside transport inhibitor and PDE3 inhibitor class that inhibits blood clot formation when given chronically and causes blood vessel dilation when given at high doses over a short time.

Cilostazol, sold under the brand name Pletal among others, is a medication used to help the symptoms of intermittent claudication in peripheral vascular disease. It may also be used to prevent stroke. It is taken by mouth.

class of pharmaceuticals that decrease platelet aggregation and inhibit thrombus formation

Aloxiprin (or aluminium acetylsalicylate) is a medication used for the treatment of pain and inflammation associated with muscular skeletal and joint disorders. It is used for its properties as an anti-inflammatory, antipyretic and analgesic drug. It is a chemical compound of aluminium hydroxide and aspirin.

Triflusal is a platelet aggregation inhibitor that was discovered and developed in the Uriach Laboratories, and commercialised in Spain since 1981. Currently, it is available in 25 countries in Europe, Asia, Africa and America. It is a derivative of acetylsalicylic acid (ASA; Aspirin) in which a hydrogen atom on the benzene ring has been replaced by a trifluoromethyl group. Trade names include Disgren, Grendis, Aflen and Triflux.

chemical compound

Indobufen is a platelet aggregation inhibitor. It acts as a reversible cyclooxygenase inhibitor.

Ditazole is a non-steroidal anti-inflammatory agent with analgesic and antipyretic activity similar to phenylbutazone. It is also a platelet aggregation inhibitor which is marketed in Spain and Portugal under the trade name Ageroplas.

Picotamide is a platelet aggregation inhibitor. It works as a thromboxane synthase inhibitor and a thromboxane receptor inhibitor, the latter by modifying cellular responses to activation of the thromboxane receptor. Picotamide is licensed in Italy for the treatment of clinical arterial thrombosis and peripheral artery disease.

Ramatroban (INN; also known as BAY u3405) is a thromboxane receptor antagonist. It is also a DP2 receptor antagonist.

Sarpogrelate (, ), sold under the brand names Anplag and Sapodifil, is a serotonin 5-HT2 receptor antagonist which is used in the treatment of arterial occlusive disorders such as peripheral artery disease in Japan, South Korea, and China. Development in the United States and the European Union was discontinued and it is not available in these regions.

Terutroban is an antiplatelet agent developed by Servier Laboratories. It is a selective thromboxane prostanoid (TP) antagonist and is an orally active drug in clinical development for the secondary prevention of acute thrombotic complications.

Terbogrel (INN) is an experimental drug that has been studied for its potential to prevent the vasoconstricting and platelet-aggregating action of thromboxanes. Terbogrel is an orally available thromboxane A2 receptor antagonist and a thromboxane A synthase inhibitor. The drug was developed by Boehringer Ingelheim.